eMedicine Specialties > Rheumatology > Crystal-Induced Arthritis

Gout: Differential Diagnoses & Workup

Author: Anne V Miller, MD, Assistant Professor of Medicine, Division of Rheumatology, Southern Illinois University School of Medicine
Coauthor(s): Sriya K M Ranatunga, MD, MPH,, Assistant Professor, Department of Clinical Medicine, Southern Illinois University School of Medicine; Mark L Francis, MD, Chief, Associate Professor, Department of Internal Medicine, Division of Rheumatology, Southern Illinois University School of Medicine
Contributor Information and Disclosures

Updated: Feb 20, 2009

Differential Diagnoses

Calcium Pyrophosphate Deposition Disease
Reactive Arthritis
Cellulitis
Rheumatoid Arthritis
Gonococcal Arthritis
Sarcoidosis
Nephrolithiasis
Septic Arthritis
Nephropathy, Uric Acid
Psoriatic Arthritis

Other Problems to Be Considered

Hypoxanthine-guanine phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome)
Phosphoribosylpyrophosphate synthetase superactivity
Congenital fructose intolerance

Workup

Laboratory Studies

  • Synovial fluid: When a patient presents with acute inflammatory monoarticular arthritis, aspiration of the involved joint is critical to rule out an infectious arthritis and to attempt to confirm a diagnosis of gout or pseudogout based on identification of crystals.

    Gout. Fluid obtained from a tophaceous deposit in...

    Gout. Fluid obtained from a tophaceous deposit in a patient with gout.

    Gout. Fluid obtained from a tophaceous deposit in...

    Gout. Fluid obtained from a tophaceous deposit in a patient with gout.

    • The critical and essential study is synovial fluid analysis to identify urate crystals. Finding intracellular urate crystals with polarizing light microscopy firmly establishes the diagnosis of gouty arthritis.
    • Urate crystals are shaped like needles or toothpicks with pointed ends.

      Gout. Needles of urate on polarizing microscopy.

      Gout. Needles of urate on polarizing microscopy.

      Gout. Needles of urate on polarizing microscopy.

      Gout. Needles of urate on polarizing microscopy.

    • Urate crystals are negatively birefringent, meaning that the crystals are yellow when aligned parallel to the slow ray of the compensator and that they are blue when they are perpendicular.

      Gout. Strongly negative birefringent, needle-shap...

      Gout. Strongly negative birefringent, needle-shaped crystals diagnostic of gout obtained from an acutely inflamed joint.

      Gout. Strongly negative birefringent, needle-shap...

      Gout. Strongly negative birefringent, needle-shaped crystals diagnostic of gout obtained from an acutely inflamed joint.

    • Pseudogout crystals (calcium pyrophosphate) are rod-shaped with blunt ends.
    • Pseudogout crystals are positively birefringent. Pragmatically, this means that their colors are opposite those of gout. Thus, pseudogout crystals are blue when aligned parallel to the slow ray of the compensator and yellow when they are perpendicular.
    • Crystals need to be distinguished from birefringent cartilaginous or other debris. Debris may have fuzzy borders and may be curved, whereas crystals have sharp borders and are straight.
    • Corticosteroids injected into joints have a crystalline structure that can mimic monosodium urate crystals. They can be either positively or negatively birefringent.
    • The sensitivity of a synovial fluid analysis for crystals is 84%, with a specificity of 100%. If gout remains a clinical consideration after negative analysis findings, the procedure can be repeated in another joint or with a subsequent flare. Crystals may be absent very early in a flare.
    • While the sensitivity is inferior, urate crystals can be identified from synovial fluid aspirated from previously inflamed joints that are not currently inflamed. Such crystals are generally extracellular.
    • Minute quantities of fluid in the shaft or hub of the needle are sufficient for synovial fluid analysis.
    • Once a diagnosis of gout is established based on confirmation of crystals, joints do not need repeat aspiration with subsequent flares unless infection is suggested or the flare does not respond appropriately to therapy for acute gout.
    • In patients with acute monoarticular arthritis, send synovial fluid for Gram stain and culture and sensitivity. The culture also provides sensitivities for antibiotic management.
    • Synovial fluid should also be sent for cell count.
    • During acute attacks, the synovial fluid is inflammatory, with a WBC count greater than 2000/µL (class II fluid) and possibly greater than 50,000/µL, with a predominance of polymorphonuclear neutrophils.
    • Synovial fluid glucose levels are usually normal, whereas they may be depressed in septic arthritis and occasionally in rheumatoid arthritis. Measurement of synovial fluid protein has no clinical value.
    • Crystalline arthritis and infectious arthritis can coexist. Indeed, infectious arthritis is more common in previously damaged joints, which may occur in patients with chronic gouty arthritis.
  • Serum uric acid
    • This is the most misused test in the diagnosis of gout. The presence of hyperuricemia in the absence of symptoms is not diagnostic of gout. In addition, as many as 10% of patients with symptoms due to gout may have normal serum uric acid levels at the time of their attack. Thus, the correct diagnosis of gout can be missed if the joint is not aspirated. Remember that situations that decrease uric acid levels can trigger attacks of gout. In such cases, the patient's prior medical records may reveal prior elevations of uric acid.
    • Five to eight percent of the population has elevated serum uric acid levels (>7 mg/dL), but only 5-20% of patients with hyperuricemia develop gout. Thus, an elevated serum uric acid level does not indicate or predict gout. As noted above, gout is diagnosed based on the discovery of urate crystals in the synovial fluid or soft tissues. More importantly, some patients with infectious arthritis present with a hot swollen joint and an elevated serum uric acid level and are at risk of being mismanaged if their synovial fluid is not aspirated to rule out septic arthritis.
    • Asymptomatic hyperuricemia should generally not be treated. However, patients with levels higher than 11 mg/dL and overexcretion of uric acid are at risk for renal stones and renal impairment; therefore, renal function should be monitored in these individuals.15
    • The level of serum uric acid correlates with risk for developing gout. The 5-year risk for developing gout is approximately 0.6% if the level is less than 7.9 mg/dL, 1% if 8-8.9 mg/dL, and 22% if higher than 9 mg/dL.
  • Uric acid in 24-hour urine sample
    • A 24-hour urinary uric acid evaluation is generally performed if uricosuric therapy is being considered.
    • If patients excrete more than 800 mg of uric acid in 24 hours on a regular diet, they are overexcretors and thus overproducers of uric acid. These patients (approximately 10% of patients with gout) require allopurinol instead of probenecid to reduce uric acid levels.
    • Patients who excrete more than 1100 mg in 24 hours should undergo close renal function monitoring because of the risk of stones and urate nephropathy.
    • In patients in whom probenecid is contraindicated (eg, those with a history of renal stones or renal insufficiency), a 24-hour urine test of uric acid excretion does not need to be performed because the patient clearly will need allopurinol.
  • Blood chemistry
    • Obtaining an accurate measure of the patient's renal function before deciding on therapy for gout is important, since the serum creatinine evaluation alone can underestimate renal dysfunction in elderly patients or in patients with low muscle mass.
    • Patients with gout are at an increased risk of developing diabetes mellitus.
    • Abnormal liver function tests need to be considered when therapy is selected.
  • CBC count: The WBC count may be elevated in patients during the acute gouty attack, particularly if it is polyarticular.
  • Lipids: Hypertriglyceridemia and low high-density lipoproteins are associated with gout.
  • Urinalysis: Patients with gout are at an increased risk of renal stones; therefore, these patients may have a history of hematuria.

Imaging Studies

  • Radiography
    • Plain radiographs may show findings consistent with gout, but these findings are not diagnostic. The most common radiographic findings early in the disease include soft-tissue swelling or an absence of abnormalities.
    • Haziness suggestive of tophi can be seen in late gout, and tophi may calcify.
    • Erosions that are not typical of rheumatoid arthritis may suggest gout.
      • Erosions with maintenance of the joint space
      • Erosions without periarticular osteopenia
      • Erosions outside the joint capsule
      • Erosions with overhanging edges

        Gout. Radiograph of erosions with overhanging edg...

        Gout. Radiograph of erosions with overhanging edges.

        Gout. Radiograph of erosions with overhanging edg...

        Gout. Radiograph of erosions with overhanging edges.

      • Erosions with sclerotic borders, sometimes called cookie-cutter or punched-out borders
      • Erosions that are distributed asymmetrically among the joints, with strong predilection for distal joints, especially in the lower extremities

        Gout. Plain radiograph showing typical changes of...

        Gout. Plain radiograph showing typical changes of gout in the first metatarsophalangeal joint and fourth interphalangeal joint.

        Gout. Plain radiograph showing typical changes of...

        Gout. Plain radiograph showing typical changes of gout in the first metatarsophalangeal joint and fourth interphalangeal joint.



        Gout. Plain radiograph showing chronic tophaceous...

        Gout. Plain radiograph showing chronic tophaceous gouty arthritis in the hands.

        Gout. Plain radiograph showing chronic tophaceous...

        Gout. Plain radiograph showing chronic tophaceous gouty arthritis in the hands.

Procedures

Perform arthrocentesis to rule out an infectious arthritis and to establish a crystal-proven diagnosis of gout. Tophi also may be aspirated for crystal analysis under polarizing microscopy.

Histologic Findings

Tophi have been found in all tissues except the brain. However, monosodium urate dissolves in formalin; therefore, only the ghosts of urate crystals may be seen if formalin is used. Alcohol-fixed tissue is best for identification of urate crystals.

More on Gout

Overview: Gout
Differential Diagnoses & Workup: Gout
Treatment & Medication: Gout
Follow-up: Gout
Multimedia: Gout
References

References

  1. Terkeltaub RA, Dyer CA, Martin J, et al. Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. J Clin Invest. Jan 1991;87(1):20-6. [Medline].

  2. Terkeltaub R, Smeltzer D, Curtiss LK, et al. Low density lipoprotein inhibits the physical interaction of phlogistic crystals and inflammatory cells. Arthritis Rheum. Mar 1986;29(3):363-70. [Medline].

  3. Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. Sep 2005;52(9):2936-46. [Medline].

  4. Nagase M, Baker DG, Schumacher HR Jr. Immunoglobulin G coating on crystals and ceramics enhances polymorphonuclear cell superoxide production: correlation with immunoglobulin G adsorbed. J Rheumatol. Jul 1989;16(7):971-6. [Medline].

  5. Ortiz-Bravo E, Sieck MS, Schumacher HR Jr. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum. Sep 1993;36(9):1274-85. [Medline].

  6. Akahoshi T, Murakami Y, Kitasato H. Recent advances in crystal-induced acute inflammation. Curr Opin Rheumatol. Mar 2007;19(2):146-50. [Medline].

  7. Terkeltaub RA. What stops a gouty attack?. J Rheumatol. Jan 1992;19(1):8-10. [Medline].

  8. Yagnik DR, Evans BJ, Florey O, et al. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. Jul 2004;50(7):2273-80. [Medline].

  9. Lioté F, Ea HK. Recent developments in crystal-induced inflammation pathogenesis and management. Curr Rheumatol Rep. Jun 2007;9(3):243-50. [Medline].

  10. Feig DI, Johnson RJ. The role of uric acid in pediatric hypertension. J Ren Nutr. Jan/2007;17(1):79-83. [Medline].

  11. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. May 26 2008;168(10):1104-10. [Medline].

  12. Puig JG, Michan AD, Jimenez ML, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med. Apr 1991;151(4):726-32. [Medline].

  13. Meyers OL, Monteagudo FS. Gout in females: an analysis of 92 patients. Clin Exp Rheumatol. Apr-Jun 1985;3(2):105-9. [Medline].

  14. Macfarlane DG, Dieppe PA. Diuretic-induced gout in elderly women. Br J Rheumatol. May 1985;24(2):155-7. [Medline].

  15. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. Mar 1987;82(3):421-6. [Medline].

  16. Medsafe Pharmacovigilance Team. Colchicine: lower doses for greater safety. Available at http://www.medsafe.govt.nz/profs/puarticles/colchdose.htm. Accessed October 3, 2008.

  17. [Best Evidence] Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. Oct 2006;65(10):1312-24. [Medline].

  18. FDA takes action to stop the marketing of unapproved injectable drugs containing colchicine. US Food and Drug Administration. Available at www.fda.gov/bbs/topics/news/2008/new01791.html. Accessed September 30, 2008.

  19. Yu T. The efficacy of colchicine prophylaxis in articular gout--a reappraisal after 20 years. Semin Arthritis Rheum. Nov 1982;12(2):256-64. [Medline].

  20. [Guideline] Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. Feb 1991;18(2):264-9. [Medline].

  21. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. Jan 1986;29(1):82-7. [Medline].

  22. Vázquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. Oct 2001;60(10):981-3. [Medline].

  23. Fels E, Sundy JS. Refractory gout: what is it and what to do about it?. Curr Opin Rheumatol. Mar 2008;20(2):198-202. [Medline].

  24. Fam AG, Dunne SM, Iazzetta J, et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. Jan 2001;44(1):231-8. [Medline].

  25. Walz-LeBlanc BA, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum. Oct 1991;34(10):1329-31. [Medline].

  26. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. Aug 2004;50(8):2400-14. [Medline].

  27. Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. Dec 1987;26(6):445-9. [Medline].

  28. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. Dec 8 2005;353(23):2450-61. [Medline].

  29. Huang HY, Appel LJ, Choi MJ, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. Jun 2005;52(6):1843-7. [Medline].

  30. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. [Medline].

  31. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. Apr 17 2004;363(9417):1277-81. [Medline].

Further Reading

Keywords

gout, uric acid metabolism, chronic tophaceous gout, tophaceous gout, gouty arthritis, primary gout, secondary gout, acute gout, chronic gout, pseudogout, polyarticular gout, saturnine gout, hyperuricemia, cyclosporin A, acute monoarticular arthritis, podagra, polyarticular arthritis, uric acid, inflammasome, anakinra, interleukin 1, joint inflammation, joint destruction

Contributor Information and Disclosures

Author

Anne V Miller, MD, Assistant Professor of Medicine, Division of Rheumatology, Southern Illinois University School of Medicine
Anne V Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, and International Society for Clinical Densitometry
Disclosure: Nothing to disclose.

Coauthor(s)

Sriya K M Ranatunga, MD, MPH,, Assistant Professor, Department of Clinical Medicine, Southern Illinois University School of Medicine
Disclosure: Nothing to disclose.

Mark L Francis, MD, Chief, Associate Professor, Department of Internal Medicine, Division of Rheumatology, Southern Illinois University School of Medicine
Mark L Francis, MD is a member of the following medical societies: American Association of Immunologists, American College of Physicians, American College of Rheumatology, American Medical Association, Illinois State Medical Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Lawrence H Brent, MD, Associate Professor of Medicine, Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center
Lawrence H Brent, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Physicians, and American College of Rheumatology
Disclosure: Genentech Honoraria Speaking and teaching; Genentech Grant/research funds Other; Amgen Honoraria Speaking and teaching; Wyeth Honoraria Speaking and teaching; Abbott Immunology Honoraria Speaking and teaching; Takeda Honoraria Speaking and teaching; UCB  Speaking and teaching; Omnicare Consulting fee Consulting; Centocor Consulting fee Consulting; Roche Grant/research funds Other

CME Editor

Alex J Mechaber, MD, FACP, Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine
Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine
Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD, Professor of Medicine, Temple University School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital
Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa
Disclosure: medifocus Honoraria Review panel membership; health dialogs Honoraria Consulting; West Penn Allegheny Health System None Board membership

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.